Zevra Therapeutics Inc (NASDAQ: ZVRA) has reported E.P.S. of $-0.67 for its fourth fiscal quarter (ending December 31) versus $-0.54 for the same period a year ago. Relative to the consensus estimate of $-0.40, this was a shortfall of $-0.27. For the latest four quarters through December 31, E.P.S. were $-2.28 compared to $-1.30 a year ago.
Recent Price Action
On 3/11/25, Zevra Therapeutics Inc (NASDAQ: ZVRA) stock rose modestly by 0.9%, closing at $8.07. Moreover, unusually high trading volume at 172% of normal accompanied the advance. Relative to the market the stock has been exceptionally strong over the last nine months and has risen 10.1% during the last week.
Current PriceTarget Research Rating
Zevra Therapeutics has a current Value Trend Rating of C (Low Neutral). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing very contradictory signals. Zevra Therapeutics has a very low Appreciation Score of 2 but a very high Power Rating of 88, producing the Low Neutral Value Trend Rating.
Rating Review
In light of this new information and positive market action we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment